Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lung Cancer: The Phase II TRUST-I Study.

Wei LiAnwen XiongNong YangHuijie FanQitao YuYanqiu ZhaoYongsheng WangXue MengJingxun WuZiping WangYunpeng LiuXicheng WangXintian QinKaihua LuWu ZhuangYizhong RenXianyu ZhangBing YanChristine M Lovly Caicun Zhou

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)

Taletrectinib continues to show high and durable overall responses, prolonged PFS, robust activity against intracranial lesions and acquired resistance mutations including G2032R, and a favorable safety profile with a low incidence of neurologic TEAEs.

Keyphrases

phase ii
clinical trial
open label
risk factors
dna damage
cell death
healthcare
randomized controlled trial
double blind
placebo controlled
health information
oxidative stress
study protocol
optical coherence tomography